Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.

van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW.

Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15.

2.

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.

Jauw YWS, Heijtel DF, Zijlstra JM, Hoekstra OS, de Vet HCW, Vugts DJ, Verheul HM, Boellaard R, Zweegman S, van Dongen GAMS, der Houven van Oordt CWM, Lammertsma AA, Huisman MC.

Mol Imaging Biol. 2018 Apr 30. doi: 10.1007/s11307-018-1200-4. [Epub ahead of print]

PMID:
29713958
3.

In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with 195mPt and 89Zr.

Muns JA, Montserrat V, Houthoff HJ, Codée-van der Schilden K, Zwaagstra O, Sijbrandi NJ, Merkul E, van Dongen GAMS.

J Nucl Med. 2018 Jul;59(7):1146-1151. doi: 10.2967/jnumed.117.206672. Epub 2018 Mar 1.

PMID:
29496986
4.

Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe.

Heuveling DA, Karagozoglu KH, Van Lingen A, Hoekstra OS, Van Dongen GAMS, De Bree R.

EJNMMI Res. 2018 Feb 14;8(1):15. doi: 10.1186/s13550-018-0368-6.

5.

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.

Jauw YWS, Huisman MC, Nayak TK, Vugts DJ, Christen R, Naegelen VM, Ruettinger D, Heil F, Lammertsma AA, Verheul HMW, Hoekstra OS, van Dongen GAMS, Menke-van der Houven van Oordt CW.

EJNMMI Res. 2018 Jan 22;8(1):6. doi: 10.1186/s13550-018-0358-8.

6.

Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.

Hagens MH, Killestein J, Yaqub MM, van Dongen GA, Lammertsma AA, Barkhof F, van Berckel BN.

Mult Scler. 2018 Apr;24(4):543-545. doi: 10.1177/1352458517704507. Epub 2017 Apr 26.

7.

Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts.

Slobbe P, Windhorst AD, Adamzek K, Bolijn M, Schuit RC, Heideman DAM, van Dongen GAMS, Poot AJ.

Oncotarget. 2017 Jun 13;8(24):38337-38350. doi: 10.18632/oncotarget.16321.

8.

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Jauw YW, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, van Dongen GA, Huisman MC.

PLoS One. 2017 Jan 6;12(1):e0169828. doi: 10.1371/journal.pone.0169828. eCollection 2017.

9.

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.

Even AJ, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJ, Heukelom J, Tesselaar ME, Vogel WV, Hoeben A, Zegers CM, Vugts DJ, van Dongen GA, Bartelink H, Mottaghy FM, Hoebers F, Lambin P.

Oncotarget. 2017 Jan 17;8(3):3870-3880. doi: 10.18632/oncotarget.13910.

10.

A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.

Sijbrandi NJ, Merkul E, Muns JA, Waalboer DC, Adamzek K, Bolijn M, Montserrat V, Somsen GW, Haselberg R, Steverink PJ, Houthoff HJ, van Dongen GA.

Cancer Res. 2017 Jan 15;77(2):257-267. doi: 10.1158/0008-5472.CAN-16-1900. Epub 2016 Nov 21.

11.

Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma.

Jansen MH, Veldhuijzen van Zanten SEM, van Vuurden DG, Huisman MC, Vugts DJ, Hoekstra OS, van Dongen GA, Kaspers GL.

J Nucl Med. 2017 May;58(5):711-716. doi: 10.2967/jnumed.116.180216. Epub 2016 Oct 20.

12.

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET.

Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, Mari C, Visser GW, Valverde IE, Gasser G, Mindt TL, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):286-295. doi: 10.1007/s00259-016-3499-x. Epub 2016 Aug 30.

13.

Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.

Slobbe P, Poot AJ, Haumann R, Schuit RC, Windhorst AD, van Dongen GA.

Nucl Med Biol. 2016 Oct;43(10):612-24. doi: 10.1016/j.nucmedbio.2016.07.003. Epub 2016 Jul 14.

PMID:
27497236
14.

Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.

Jansen MH, Lagerweij T, Sewing AC, Vugts DJ, van Vuurden DG, Molthoff CF, Caretti V, Veringa SJ, Petersen N, Carcaboso AM, Noske DP, Vandertop WP, Wesseling P, van Dongen GA, Kaspers GJ, Hulleman E.

Mol Cancer Ther. 2016 Sep;15(9):2166-74. doi: 10.1158/1535-7163.MCT-15-0558. Epub 2016 Jun 20.

15.

Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

Bahce I, Yaqub M, Smit EF, Lammertsma AA, van Dongen GA, Hendrikse NH.

Lung Cancer. 2017 May;107:1-13. doi: 10.1016/j.lungcan.2016.05.025. Epub 2016 May 31. Review.

16.

HDL mimetic CER-001 targets atherosclerotic plaques in patients.

Zheng KH, van der Valk FM, Smits LP, Sandberg M, Dasseux JL, Baron R, Barbaras R, Keyserling C, Coolen BF, Nederveen AJ, Verberne HJ, Nell TE, Vugts DJ, Duivenvoorden R, Fayad ZA, Mulder WJM, van Dongen GAMS, Stroes ESG.

Atherosclerosis. 2016 Aug;251:381-388. doi: 10.1016/j.atherosclerosis.2016.05.038. Epub 2016 May 27.

17.

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?

Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, Huisman MC, van Dongen GA.

Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131. eCollection 2016. Review.

18.

(89) Zr-rituximab PET/CT to detect neurolymphomatosis.

de Jong A, Mous R, van Dongen GA, Hoekstra OS, Nievelstein RA, de Keizer B.

Am J Hematol. 2016 Jun;91(6):649-50. doi: 10.1002/ajh.24328. Epub 2016 Apr 13. No abstract available.

19.

89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.

Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, Mulder ER, Schuit RC, Boellaard R, Hoekstra OS, van Dongen GA, Verheul HM.

Oncotarget. 2015 Oct 6;6(30):30384-93. doi: 10.18632/oncotarget.4672.

20.

Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer.

Bahce I, Huisman MC, Verwer EE, Ooijevaar R, Boutkourt F, Vugts DJ, van Dongen GA, Boellaard R, Smit EF.

EJNMMI Res. 2014 Dec;4(1):35. doi: 10.1186/s13550-014-0035-5. Epub 2014 Aug 2.

21.

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.

Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ.

EJNMMI Res. 2015 Mar 20;5:14. doi: 10.1186/s13550-015-0088-0. eCollection 2015.

22.

Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model.

Waalboer DC, Muns JA, Sijbrandi NJ, Schasfoort RB, Haselberg R, Somsen GW, Houthoff HJ, van Dongen GA.

ChemMedChem. 2015 May;10(5):797-803. doi: 10.1002/cmdc.201402496. Epub 2015 Mar 25.

PMID:
25809281
23.

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14. doi: 10.1007/s00259-015-3025-6. Epub 2015 Mar 20.

24.

PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.

Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GA, Verheul HM, Menke CW, Huisman MC.

J Nucl Med. 2015 Feb;56(2):249-54. doi: 10.2967/jnumed.114.147819. Epub 2015 Jan 22.

25.

89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied?

Van Dongen GA, Huisman MC, Boellaard R, Harry Hendrikse N, Windhorst AD, Visser GW, Molthoff CF, Vugts DJ.

Q J Nucl Med Mol Imaging. 2015 Mar;59(1):18-38. Epub 2014 Dec 17. Review.

PMID:
25517081
26.

A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.

Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, Dubois L, Lambin P.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):351-9. doi: 10.1016/j.ijrobp.2014.09.045. Epub 2014 Dec 6.

27.

Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.

Cohen R, Vugts DJ, Visser GW, Stigter-van Walsum M, Bolijn M, Spiga M, Lazzari P, Shankar S, Sani M, Zanda M, van Dongen GA.

Cancer Res. 2014 Oct 15;74(20):5700-10. doi: 10.1158/0008-5472.CAN-14-1141. Epub 2014 Aug 21.

28.

Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.

Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ.

Nucl Med Biol. 2014 Oct;41(9):749-57. doi: 10.1016/j.nucmedbio.2014.06.005. Epub 2014 Jun 25.

PMID:
25066021
29.

Three-dimensional histologic validation of high-resolution SPECT of antibody distributions within xenografts.

Branderhorst W, Blezer EL, Houtkamp M, Ramakers RM, van den Brakel JH, Witteveen H, van der Have F, Gratama van Andel HA, Vastenhouw B, Wu C, Walsum MS, van Dongen GA, Viergever MA, Bleeker WK, Beekman FJ.

J Nucl Med. 2014 May;55(5):830-7. doi: 10.2967/jnumed.113.125401. Epub 2014 Mar 31.

30.

Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.

Vugts DJ, Heuveling DA, Stigter-van Walsum M, Weigand S, Bergstrom M, van Dongen GA, Nayak TK.

MAbs. 2014 Mar-Apr;6(2):567-75. doi: 10.4161/mabs.27415. Epub 2013 Dec 9.

31.

Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

Gaillard PJ, Appeldoorn CC, Dorland R, van Kregten J, Manca F, Vugts DJ, Windhorst B, van Dongen GA, de Vries HE, Maussang D, van Tellingen O.

PLoS One. 2014 Jan 8;9(1):e82331. doi: 10.1371/journal.pone.0082331. eCollection 2014.

32.

Multicenter harmonization of 89Zr PET/CT performance.

Makris NE, Boellaard R, Visser EP, de Jong JR, Vanderlinden B, Wierts R, van der Veen BJ, Greuter HJ, Vugts DJ, van Dongen GA, Lammertsma AA, Huisman MC.

J Nucl Med. 2014 Feb;55(2):264-7. doi: 10.2967/jnumed.113.130112. Epub 2013 Dec 19.

33.

Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.

Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, van Dongen GA, Merchiers P, van Rompaey P, Smit MJ.

J Biol Chem. 2013 Oct 11;288(41):29562-72. doi: 10.1074/jbc.M113.498436. Epub 2013 Aug 26.

34.

ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.

Stillebroer AB, Franssen GM, Mulders PF, Oyen WJ, van Dongen GA, Laverman P, Oosterwijk E, Boerman OC.

Cancer Biother Radiopharm. 2013 Sep;28(7):510-5. doi: 10.1089/cbr.2013.1487. Epub 2013 May 22.

35.

Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging.

Cohen R, Vugts DJ, Stigter-van Walsum M, Visser GW, van Dongen GA.

Nat Protoc. 2013 May;8(5):1010-8. doi: 10.1038/nprot.2013.054. Epub 2013 Apr 25.

PMID:
23619892
36.

EATRIS, a European initiative to boost translational biomedical research.

van Dongen GA, Ussi AE, de Man FH, Migliaccio G.

Am J Nucl Med Mol Imaging. 2013;3(2):166-74. Epub 2013 Mar 8.

37.

[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.

Poot AJ, van der Wildt B, Stigter-van Walsum M, Rongen M, Schuit RC, Hendrikse NH, Eriksson J, van Dongen GA, Windhorst AD.

Nucl Med Biol. 2013 May;40(4):488-97. doi: 10.1016/j.nucmedbio.2013.02.002. Epub 2013 Mar 20.

38.

89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals.

Vugts DJ, Visser GW, van Dongen GA.

Curr Top Med Chem. 2013;13(4):446-57. Review.

PMID:
23432007
39.

Pilot study on the feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for sentinel node identification in oral cancer patients.

Heuveling DA, van Schie A, Vugts DJ, Hendrikse NH, Yaqub M, Hoekstra OS, Karagozoglu KH, Leemans CR, van Dongen GA, de Bree R.

J Nucl Med. 2013 Apr;54(4):585-9. doi: 10.2967/jnumed.112.115188. Epub 2013 Feb 1.

40.

Imaging of TKI-target interactions for personalized cancer therapy.

Poot AJ, Slobbe P, Hendrikse NH, Windhorst AD, van Dongen GA.

Clin Pharmacol Ther. 2013 Mar;93(3):239-41. doi: 10.1038/clpt.2012.242. Epub 2012 Dec 12. No abstract available.

PMID:
23340475
41.

Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.

Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS, Leemans CR, Neri D, van Dongen GA.

J Nucl Med. 2013 Mar;54(3):397-401. doi: 10.2967/jnumed.112.111310. Epub 2013 Jan 18.

42.

A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies.

Oliveira S, Cohen R, Walsum MS, van Dongen GA, Elias SG, van Diest PJ, Mali W, van Bergen En Henegouwen PM.

EJNMMI Res. 2012 Sep 25;2(1):50. doi: 10.1186/2191-219X-2-50.

43.

PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.

Slobbe P, Poot AJ, Windhorst AD, van Dongen GA.

Drug Discov Today. 2012 Nov;17(21-22):1175-87. doi: 10.1016/j.drudis.2012.06.016. Epub 2012 Jul 2. Review.

PMID:
22766374
44.

Public-private partnerships in translational medicine: concepts and practical examples.

Luijten PR, van Dongen GA, Moonen CT, Storm G, Crommelin DJ.

J Control Release. 2012 Jul 20;161(2):416-21. doi: 10.1016/j.jconrel.2012.03.012. Epub 2012 Mar 20. Review.

PMID:
22465390
45.

Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.

Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM.

Mol Imaging. 2012 Feb;11(1):33-46.

PMID:
22418026
46.

Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node.

Heuveling DA, Visser GW, de Groot M, de Boer JF, Baclayon M, Roos WH, Wuite GJ, Leemans CR, de Bree R, van Dongen GA.

Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1161-8. doi: 10.1007/s00259-012-2080-5. Epub 2012 Feb 17.

47.

Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.

Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA.

Mol Cancer Ther. 2012 Apr;11(4):1017-25. doi: 10.1158/1535-7163.MCT-11-0891. Epub 2012 Feb 7.

48.

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.

van Dongen GA, Poot AJ, Vugts DJ.

Tumour Biol. 2012 Jun;33(3):607-15. doi: 10.1007/s13277-012-0316-4. Epub 2012 Jan 21. Review.

49.

Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.

Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GA, Lubberink M.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):512-20. doi: 10.1007/s00259-011-2008-5. Epub 2012 Jan 5.

50.

Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets.

Cohen R, Stammes MA, de Roos IH, Stigter-van Walsum M, Visser GW, van Dongen GA.

EJNMMI Res. 2011 Dec 1;1(1):31. doi: 10.1186/2191-219X-1-31.

Supplemental Content

Loading ...
Support Center